Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial-Reference-Cited by-同舟云学术

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Published:2016-07 Issue:7 Volume:17 Page:956-965
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Seiwert Tanguy Y,Burtness Barbara,Mehra Ranee,Weiss Jared,Berger Raanan,Eder Joseph Paul,Heath Karl,McClanahan Terrill,Lunceford Jared,Gause Christine,Cheng Jonathan D,Chow Laura Q

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. The chemoradiation paradigm in head and neck cancer;Seiwert;Nat Clin Pract Oncol,2007

2. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

3. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas;Seiwert;Clin Cancer Res,2015

4. Comprehensive genomic characterization of head and neck squamous cell carcinomas;Nature,2015

5. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes;Keck;Clin Cancer Res,2015

Cited by 1400 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in Head and Neck Cancer;Surgical Oncology Clinics of North America;2024-10

2. Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC);Oral Oncology Reports;2024-09

3. Emerging Immune Checkpoint Inhibitors for the Treatment of Oropharyngeal Squamous Cell Carcinoma;Oral Oncology Reports;2024-09

4. A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer;Oral Oncology Reports;2024-09

5. Rechallenge de l’immunothérapie par nivolumab pour un cancer épidermoïde du larynx en poursuite évolutive après échec des modalités conventionnelles de traitement : cas clinique CARE;Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale;2024-09